Genedata, a leading provider of advanced software solutions for R&D, celebrates this month its 20th anniversary, marking the occasion with a strong presence at Bio-IT World Conference & Expo 2017 in Boston, MA. Genedata is sponsoring the meeting’s Welcome Reception and further extends an invitation to all attendees to view posters on the entire range of Genedata software platforms. Conference delegates are also invited to visit the Genedata booth (#238–240) at the Expo to discuss the latest developments in the company’s rapidly expanding software portfolio.
Genedata commenced operations on May 1, 1997 and has grown from a pioneering bioinformatics start-up to a team of more than 200 scientific and computational experts. The company, still headquartered in Basel, Switzerland, has established subsidiaries in the US, Germany, Japan and the UK, with plans to open additional offices around the world in the near future.
Genedata has evolved into a global leader in enterprise software systems for biopharmaceutical R&D based on a deep understanding of the underlying sciences and applied technologies and with a vision to enable the promise of precision medicine. Driven by the goal to improve the efficiency of the biopharmaceutical R&D process, today Genedata provides highly innovative software solutions for a variety of R&D workflows, such as in vitro screening, biologics discovery, bioprocess development, omics-based patient profiling and precise genome editing using for example CRISPR. Besides providing a range of integrative software platforms, the company has also established a consulting business that supports its clients in harmonizing and automating complex, large-scale experimental processes in order to maximize the ROI from their R&D.
Genedata was founded with the aim of providing software that meets the rapidly changing and expanding challenges of large-scale data analytics in R&D-driven companies. Today, the world’s leading biopharmaceutical and biotechnology companies, as well as some of the most innovative life science research institutions, rely on Genedata to improve R&D data quality, simplify R&D workflows through automation, and drive down the time and money expended on these tasks. Genedata software frequently produces time savings of over 90% and increases process productivity by orders of magnitude while significantly improving data quality. The speed with which comprehensive, actionable reports are produced using Genedata software facilitates efficient decision-making and potentially saves millions of dollars.
All Genedata products have been developed in partnership with leading life science companies and research institutions to ensure that they meet the real-life needs of R&D organizations. All products also continue to evolve and adapt to the changing needs of clients, driven by technological and organizational progress in R&D.
“Genedata is a science-driven company,” commented Dr. Othmar Pfannes, founder and CEO of Genedata. “Working with our clients, we identify data processing problems that are critical for R&D efficiency. Then we create software to solve these problems, putting in our scientific and technical expertise. That way, we remain highly relevant and truly meet our clients’ needs. We really enjoy the innovative and challenging aspects of our work.”
Genedata celebrates at Bio-IT
Speaking just prior to opening the Welcome Reception, Dr. Pfannes stated, “We are delighted to be at Bio-IT World, an event that we have attended since its first conference some 15 years ago. I am humbled by the success of Genedata over the last two decades and am excited by the vast potential for growth in our key areas of operation—a potential that we will achieve by continuing to anticipate and meet the evolving challenges of this exciting industry.”
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.